Jan 26 |
EPIX: Updated Data for Phase 1 Trial of Masofaniten Shows 63% of Patients Achieved PSA <0.2 ng/mL…
|
Jan 25 |
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
|
Jan 22 |
ESSA Pharma Inc.'s (NASDAQ:EPIX) hedge funds investors lost 12% last week but have benefitted from longer-term gains
|
Dec 21 |
These Stocks under $10 Are Poised To Explode
|
Dec 20 |
EPIX: Initial Data from Combination Trial of Masofaniten and Enzalutamide Expected in 2024…
|
Dec 12 |
ESSA Pharma Inc (EPIX) Reports Fiscal Q4 and Full-Year Earnings, Advances in Prostate Cancer ...
|
Dec 12 |
ESSA Pharma GAAP EPS of -$0.12 beats by $0.10
|
Dec 12 |
Recap: ESSA Pharma Q4 Earnings
|
Dec 12 |
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023
|
Dec 11 |
Bullish ESSA Pharma Insiders Loaded Up On US$1.19m Of Stock
|